[Somatostatin in the prevention of postoperative increase of pancreatic enzyme after pancreatic surgery].
The prophylactic effect of perioperative use of somatostatin on postoperative increase of pancreatic digestive enzymes was investigated in this double blind, randomized study. Thirty three patients undergoing pancreatic surgery because of chronic pancreatitis were divided randomly into two groups. Fifteen patients received somatostatin- (dose 125 micrograms/hour), 18 placebo-infusion, pre- and postoperatively for a total time of 48 hours. The level of serum amylase, lipase, gammaGT, calcium, creatinine and blood glucose was determined every 12 hours. In the placebo group the serum lipase and amylase increased significantly (p less than 0.001), while the calcium decreased. In the somatostatin treated patients only the lipase level increased significantly (p less than 0.01), while the amylase and calcium showed no significant changes compared to their initial values. The postoperative increase in serum enzyme levels is interpreted as being an indicator of pancreatic injury. These results suggest that the perioperative use of somatostatin has beneficial effect for the prevention of pancreatic enzymes increases, associated with pancreatic surgery or its complications in patients with chronic pancreatitis.
Tulassay
Z
Z
Semmelweis Orvostudományi Egyetem, Budapest.
Flautner
L
L
Fehérvári
I
I
Sándor
Z
Z
Németh
J
J
D000328:Adult; D000681:Amylases / Q000037:antagonists & inhibitors; D002908:Chronic Disease; D004311:Double-Blind Method; D004341:Drug Evaluation; D004791:Enzyme Inhibitors; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D008049:Lipase / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy; D010195:Pancreatitis / Q000201:enzymology / Q000601:surgery*; D010919:Placebos; D011184:Postoperative Period
D004791:Enzyme Inhibitors; D010919:Placebos; D013006:Growth Hormone; D008049:Lipase; D000681:Amylases
Somatostatin a hasnyálmirigy-mütétek után kialakuló pancreas-enzim emelkedés megelözésében.